Drugs / Xembify
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07540221 | Apr 2026 → Dec 2027 expected | chronic inflammatory demyelinating polyradiculoneuropathy | Grifols Therapeutics LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT05645107 | Dec 2022 → May 2026 overdue | B cell deficiency, B-cell chronic lymphocytic leukemia, bacterial infectious disease, plasma cell myeloma | Grifols Therapeutics LLC | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XEMBIFY | “A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy” NCT07540221 ↗ |
| Known as | IGSC 20% | “Xembify (IGSC 20%)” NCT07540221 ↗ |
| Modality | Protein / enzyme biologic | “Immune Globulin Subcutaneous (Human), 20% (IGSC 20%)” NCT05645107 ↗ |
| Route | Subcutaneous | “SC infusion pump” NCT05645107 ↗ |